




PHARMACEUTICAL 2022

Tonix Pharmaceuticals Holding Corp.
Rank 122 of 466





PHARMACEUTICAL 2022

Tonix Pharmaceuticals Holding Corp. Rank 122 of 466

The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp. is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 216%, being 138% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	189,049
Cost of Goods Sold	0
Intangible Assets	120
Liabilities, Current	21,716
Liabilities, Non-Current	467
Other Assets	1,173
Other Compr. Net Income	-30
Other Expenses	0
Other Liabilities	0
Other Net Income	25
Other Revenues	0
Property and Equipment	50,558
Research and Development	68,838
Selling, General and Administrative Expense	23,474

Output Variable	Value in 1000 USD
Assets	240,900
Liabilities	22,183
Expenses	92,312
Revenues	0
Stockholders Equity	218,717
Net Income	-92,287
Comprehensive Net Income	-92,302
Economic Capital Ratio	216%